Leadership
Our team of passionate biopharmaceutical leaders combines deep expertise in drug development and commercialization
Meet our leadership teamLatest news
View more news > February 23, 2024
Read press release
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 15, 2024
Read press release
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
Rare perspective
Insights and information on our approach to collaborating with rare disease communities, supporting our teammates at Ultragenyx, and developing new therapies for rare disease
Read our blog >